Lucid launches 3 new test centers

By staff writers

March 23, 2022 -- Lucid Diagnostics, a Pavmed subsidiary, has launched Lucid Test Centers in Seattle, Portland, and Boise, ID. After physician referrals, patients can get tested for esophageal precancer at these centers.

The test centers are staffed with Lucid-employed nurse practitioners who use Lucid's EsoCheck cell collection device to collect surface esophageal cells. Then, the cells undergo Lucid's EsoGuard DNA esophageal test.

Lucid's tests serve as a screening tool to prevent esophageal cancer deaths through the early detection of esophageal precancer in at-risk gastroesophageal reflux disease patients.

Lucid closes Nasdaq initial public offering
The cancer prevention medical diagnostics firm Lucid Diagnostics, a subsidiary of PAVmed, has closed its initial public offering.
Lucid Diagnostics files for IPO on Nasdaq exchange
Lucid Diagnostics has filed for an initial public offering (IPO), and the company's shares will be traded on the Nasdaq stock exchange under the symbol...
Lucid launches EsoGuard pilot test at centers in Ariz.
Lucid Diagnostics has launched three test centers in Phoenix, where patients are undergoing esophageal precancer testing in a pilot test of the company's...

Copyright © 2022

Last Updated 3/23/2022 2:23:38 PM